Labocanna

Labocanna Receivables/Revenue

The Receivables to Revenue Ratio of Labocanna (LCN.WA) as of Oct 17, 2026 is 5,664.24 %. In the previous year, Receivables to Revenue Ratio was 6.06 % — a change of 93,360.03% (higher).

Receivables/Revenue

5,664.24 %

YoY

93,360.03%

Last updated:

Receivables to Revenue Ratio of Labocanna is 2022 5,664.24 % . Receivables to Revenue Ratio of Labocanna was 2021 6.06 % . It decreases by 93,360.03% higher compared to the previous year.

The Labocanna Receivables/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables/Revenue
Date
Receivables/Revenue
Jan 1, 2015
22.05 PLN
Jan 1, 2016
15.47 PLN
Jan 1, 2017
18.97 PLN
Jan 1, 2018
15.30 PLN
Jan 1, 2019
288.89 PLN
Jan 1, 2020
1,300.00 PLN
Jan 1, 2021
6.06 PLN
Jan 1, 2022
5,664.24 PLN
The Labocanna Receivables/Revenue history
YEARReceivables/RevenueYoY
5,664.24 %+93,360.03%
6.06 %-99.53%
1,300.00 %+350.00%
288.89 %+1,788.10%
15.30 %-19.36%
18.97 %+22.68%
15.47 %-29.86%
22.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labocanna Stock analysis

What does Labocanna do? Labocanna SA is a pharmaceutical company based in Koszalin, Poland, operating within the Health Care sector. The company's primary focus is on the hemp business, as indicated by its operational description. It completed its initial public offering (IPO) on July 4, 2011, marking its entry into the public market. Labocanna SA is listed under the ticker symbol LCN.WA and holds the ISIN code PLCCTLS00017. The company's headquarters are located in Koszalin, a city in the West Pomeranian Voivodeship (Woj. Zachodniopomorskie) of Poland. Its official website is https://labocanna.pl/, which serves as a primary source of information about its operations and offerings. The company operates within the pharmaceutical industry, though specific details about its products, services, or market position are not provided in the available information. Labocanna SA's activities are centered around the hemp sector, which may include the development, production, or distribution of hemp-related products, though the exact nature of these activities remains unspecified. The company's public listing and headquarters location are key identifiers for its operational and financial profile. No additional details regarding founding year, key personnel, acquisitions, or financial figures are included in the provided data. Labocanna is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labocanna stock

Receivables to Revenue Ratio of Labocanna is 5,664.24 % in 2022.

Receivables to Revenue Ratio of Labocanna changed from 6.06 % to 5,664.24 %, representing a 93,360.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Receivables to Revenue Ratio Labocanna since 2006 – with annual values, charts, and detailed analysis.

The Receivables/Revenue ratio shows what percentage of annual revenue is tied up in accounts receivable. Rising ratios may signal collection issues.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Receivables to Revenue Ratio's Labocanna with sector peers and the industry average to assess whether it is attractive.

To evaluate Receivables to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Receivables to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Labocanna

All Key Metrics — Labocanna